Search
Oxford, UK based Oxford BioTherapeutics has steadily been rolling out new partnerships, most recently with Bristol, Roche, and GSK, for its antibody and target discovery work
CEO Christian Rohlff describes the types of programs Oxford will be collaborating with these companies on, and discussed why the company has prioritized partnerships over an internal pipeline lately. Plus, details on a unique database the company has derived that could lead to even further programs and deals.
Jul 20
Oxford BioTherapeutics' OGAP platform, a cancer specific membrane protein library, has enabled the company to find cancer targets for its own pipeline and partners alike
CEO Christian Rohlff describes the expertise the company has build and describes pipeline assets, including partnerships with Boehringer,...
Sep 18, 2024
.png){kind=logo}